Modified Pore-Forming Protein Toxins and Use Thereof
The present invention provides modified pore-forming protein toxins (MPPTs), capable of being used to kill cancer cells. The MPPTs according to the present invention comprise a modification of the naturally occurring activation sequence comprising one or more general cleavage sites, each of which is cleavable by general activating agent, or a plurality of specific cleavage sites, each of which is cleavable by a specific activating agent. Optional further modifications that allow specific targeting of these molecules are also described. These MPPTs may be used to treat cancer.
1 . A broad-spectrum anti-cancer agent comprising a modified pore forming protein toxin, said modified pore forming protein toxin derived from a naturally occurring aerolysin-related pore forming protein and comprising a modified activation sequence in which a native protease cleavage site has been functionally deleted and replaced with: one or more general cleavage sites, each cleavable by an enzyme associated with a plurality of cancers, or two or more specific cleavage sites, each cleavable by an enzyme associated with the presence of a specific cancer, wherein cleavage of said modified activation sequence provides an activated pore forming protein toxin capable of killing cancer cells.
2 . The broad-spectrum anti-cancer agent according to claim 1 , wherein said aerolysin-related pore forming protein toxin is proaerolysin or Clostridium septicum alpha toxin.
3 . (canceled)
4 . The broad-spectrum anti-cancer agent according to claim 1 , wherein said enzyme associated with a plurality of cancers is a protease that is associated with cancer invasion and metastasis, a protease that is up-regulated or secreted by cancer cells, a protease that is activated by enzymes or receptors expressed by cancer cells, or a protease that is associated with angiogenesis.
5 . The broad-spectrum anti-cancer agent according to claim 1 , wherein said modified activation sequence comprises one or more general cleavage sites cleavable by urokinase-type plasminogen activator or matrix metalloprotease 2.
6 - 8 . (canceled)
9 . The broad-spectrum anti-cancer agent according to claim 5 , wherein said modified pore forming protein toxin comprises an amino acid sequence at least 90% identical to the sequence as set forth in SEQ ID NO:21 or SEQ ID NO:39.
10 - 12 . (canceled)
13 . The broad-spectrum anti-cancer agent according to claim 1 , comprising two general cleavage sites, wherein one of said general cleavage sites is cleavable by urokinase-type plasminogen activator, and the other of said general cleavage sites is cleavable by matrix metalloprotease 2.
14 . The broad-spectrum anti-cancer agent according to claim 1 , wherein said general cleavage site comprises the amino acid sequence SGRSAQ (SEQ ID NO:51).
15 . The broad-spectrum anti-cancer agent according to claim 1 , wherein said general cleavage site comprises the amino acid sequence HPVGLLAR (SEQ ID NO:52).
16 . The broad-spectrum anti-cancer agent according to claim 13 , wherein said modified pore forming protein toxin comprises an amino acid sequence at least 90% identical to the sequence as set forth in SEQ ID NO:41.
17 . The broad-spectrum anti-cancer agent according to claim 1 , wherein said modified pore forming protein toxin further comprises:
a) an artificial regulatory domain capable of targeting said modified pore forming protein toxin to a cell and/or of inhibiting the activity of said modified pore forming protein toxin;
b) one or more mutations in a native binding domain; or
c) a combination of a) and b).
18 . The broad-spectrum anti-cancer agent according to claim 17 , wherein said artificial regulatory domain is attached to said modified pore forming protein toxin via a linker wherein said artificial regulatory domain is capable of targeting said modified pore forming protein toxin to a cell and/or of inhibiting the activity of said modified pore forming protein.
19 . The broad-spectrum anti-cancer agent according to claim 18 , wherein said linker comprises an enzyme cleavage site.
20 . The broad-spectrum anti-cancer agent according to claim 19 , wherein said enzyme cleavage site is cleavable by urokinase-type plasminogen activator, matrix metalloprotease 2, Factor Xa, enterokinase, or thrombin.
21 - 24 . (canceled)
25 . The broad-spectrum anti-cancer agent according to claim 17 , wherein the targeting unit is an antibody, an antibody fragment, a steroid hormone, a peptide hormone, a neuroactive substance, insulin, a growth factor, a cytokine, melanocyte stimulating hormone, a soluble fragment of CD4, a lectin, an adhesion molecule, a selectin, an integrin, a receptor for an adhesion molecule, a recognition motif for an adhesion molecule, or an enzyme.
26 - 27 . (canceled)
28 . The broad-spectrum anti-cancer agent according to claim 17 , wherein the artificial regulatory domain is an AFAI antibody fragment.
29 . The broad-spectrum anti-cancer agent according to claim 28 , wherein said modified pore forming protein toxin comprises an amino acid sequence at least 90% identical to the sequence as set forth in SEQ ID NO:23 or SEQ ID NO:25.
30 . (canceled)
31 . The broad-spectrum anti-cancer agent according to claim 17 , wherein said one or more mutations in a native binding domain are a mutation at position Y61, a mutation at position Y162, a mutation at position W324, a mutation at position R323, a mutation at position R336, a mutation at position W 127, or a combination thereof.
32 . The broad-spectrum anti-cancer agent according to claim 31 , wherein at least one mutation is R336A or R336c.
33 . An isolated polynucleotide encoding the broad-spectrum anti-cancer agent according to claim 1 .
34 . A vector comprising the polynucleotide according to claim 33 , wherein the polynucleotide is operatively linked to one or more expression control sequences.
35 . A host cell comprising the vector according to claim 34 .
36 . A modified pore forming protein toxin derived from proaerolysin and comprising a modified activation sequence in which a native protease cleavage site has been functionally deleted and replaced with one or more general cleavage sites cleavable by urokinase-type plasminogen activator or matrix metalloprotease 2, said modified pore forming protein toxin comprising an amino acid sequence at least 90% identical to the sequence as set forth in any one of SEQ ID NOs: 21, 23, 25, 39, or 41.
37 . The broad-spectrum anti-cancer agent according to claim 1 , further comprising a pharmaceutically acceptable carrier.
38 . The isolated polynucleotide according to claim 33 , further comprising a pharmaceutically acceptable carrier.
39 - 74 . (canceled)
75 . The method of claim 76 , wherein treating cancer comprises decreasing the size of a tumor.
76 . A method of treating cancer comprising administering to a subject having cancer an effective amount of the broad-spectrum anti-cancer agent according to claim 1 .
77 . A method of preparing a broad-spectrum anti-cancer agent, said method comprising:
providing a native pore forming protein toxin wherein said native pore forming protein toxin is proaerolysin or Clostridium septicum alpha toxin; and
modifying the activation sequence of said native pore forming protein toxin such that a native protease cleavage site is functionally deleted and replaced by one or more general cleavage sites each cleavable by an enzyme associated with a plurality of cancers, or by two or more specific cleavage sites each cleavable by an enzyme associated with the presence of a specific cancer, wherein cleavage of said modified activation sequence provides an activated pore forming protein toxin capable of killing cancer cells.
78 . The broad spectrum anti-cancer agent of claim 25 , wherein the targeting unit is a cytokine.
79 . The broad spectrum anti-cancer agent of claim 78 , wherein the cytokine is interleukin-2.
80 . The broad spectrum anti-cancer agent of claim 78 , wherein said aerolysin-related pore forming protein toxin is proaerolysin or Clostridium septicum alpha toxin.
81 . The method of claim 76 , further comprising administering to the subject a therapeutically effective amount of one or more anti-cancer therapeutics.
82 . A method of treating cancer comprising administering to a subject having cancer an effective amount of the broad-spectrum anti-cancer agent according to claim 78 .
83 . The method of claim 82 , wherein the cytokine is interleukin-2.
84 . The method of claim 82 , wherein the aerolysin-related pore forming protein toxin is proaerolysin or Clostridium septicum alpha toxin.
85 . The method of claim 84 , further comprising administering to the subject a therapeutically effective amount of one or more anti-cancer therapeutics.